Bio-IT World January 23, 2026
Contributed Commentary by Daniel O’Keeffe, Qinecsa
Applying artificial intelligence (AI) to fragmented and incomplete safety data cannot fill the gap left when the right information has not been captured during initial patient adverse event reporting. And yet, software vendors position the technology as a quick fix to safety data complexity. Although AI definitely has a role to play, it would be far better to use it to refine the data capture process, driving richer safety insights and ultimately better safety outcomes. Regulators could help ensure this with a clearer mandate for professional data collectors.
The drive to ensure that pharmaceutical products and therapies are as safe as they can be—and deliver optimal outcomes—is...
Today's Sponsors
Today's Sponsor